Trinity Biotech (TRIB) investor relations material

Company overview and business model

• Commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors.

• Develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical labs, recently expanding into wearable biosensor devices, starting with continuous glucose monitoring.

• Products are sold directly in the US, Brazil, UK, Germany, France, and via distributors in about 100 countries.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $5.1 million (actual) and $7.6 million (as adjusted).

• Total debt stood at $124.6 million (actual) and $130.9 million (as adjusted).

• Shareholders’ equity was $(72.0) million (actual) and $(71.9) million (as adjusted).

• 405,017,380 ordinary shares outstanding before the offering; up to 1,080,065,960 after full sale under the agreement.

Use of proceeds and capital allocation

• May receive up to $25 million in gross proceeds from ADS sales to the Selling Securityholder under the Purchase Agreement.

• Proceeds intended for operating expenses, working capital, strategic, and general corporate purposes.

• Management has broad discretion over use of proceeds; actual amount depends on number of ADSs sold and market conditions.